CStonePharmaceuticals-B (02616) announced that the Investigational New Drug (IND) application for CS5007, one of the core candidate drugs in its Pipeline 2.0 portfolio-an EGFR/HER3 bispecific antibody-drug conjugate (ADC)-has been rapidly approved through the National Medical Products Administration (NMPA)’s review and...
Professor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong Tong University School of Medicine and principal investigator of the trial, said:" These exciting results from SAFFRON represent a critical advance for patients with EGFR- mutated...
--BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to...
--HUTCHMED Limited today announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS ® plus TAGRISSO ® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doublet platinum-based chemotherapy in...
BioTech BLSM BlossomHill Wins FDA Fast Track For BH-30643 In EGFR-Mutant NSCLC;Stock Up August 18, 2026 - 08:23 am EDT Written by RTTNews.com for RTTNews linkedin facebook x email reddit (RTTNews) - BlossomHill Therapeutics, Inc. (BLSM) announced today that the...
Non-small cell lung cancer remains a leading cause of cancer-related mortality, driven significantly by specific EGFR mutations. This study utilized a quantum-inspired immunoinformatics framework to design a novel, self-adjuvanted multi-epitope vaccine specifically targeting the atypical EGFR E709G mutation. The computational...
This study aims to compare healthcare utilization between patients with stage 3–5 chronic kidney disease (CKD) and patients with normal estimated glomerular filtration rate (n-eGFR) to identify differences in healthcare needs. This retrospective observational study included patients hospitalized in Western...
Original Article
Share on
First-Line...
SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S....
SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S....
